MGMT and breast cancer: While other biomarkers such as BCR::ABL, RUNX1::RUNX1T1, PML::RARA, and MGMT promoter methylation are being explored, there is a need to consider and evaluate genomic instability (HRD scars) as a biomarker for hematological malignancies, given it has shown promising results in identifying HR-deficient tumors in ovarian and breast cancers.